Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sensyne Health Long Term Incentive Plan

30 Sep 2020 07:01

RNS Number : 5619A
Sensyne Health PLC
30 September 2020
 

Sensyne Health

("Sensyne", the "Company" or the "Group")

 

Long term incentive plan

 

Oxford, U.K. 30 September 2020: Sensyne Health plc (LSE: SENS), the UK Clinical AI company, today announces that the Board of Directors has agreed to establish a new long-term incentive plan (the "Value Creation Plan" or "VCP") for existing and new executive directors and senior management.

 

The Non-executive directors have consulted with a number of institutional shareholders on the VCP with a view to creating a simple incentive plan that aligns the potential rewards with shareholder returns and acts as an attractive mechanism in the Company's search for new talent in a competitive field. The key terms of the VCP are summarised below:

 

· Eligible participants will be granted a percentage of a pool of value created from the growth in value of Sensyne Health's share capital after a 5-year period ending 31 March 2025.

· The pool will not begin to accrue until the target rate of 10% p.a. growth is exceeded, with a varying percentage of the growth above the target funding the VCP (see table below).

· The final value of the VCP will be calculated based upon an average of the closing share price for the 3 months prior to the end date.

· Awards will be granted to executive directors as well as key members of senior management (25% for the CEO and the remainder distributed among senior management including a reserve for new hires).

· No value will be released to the participants for a period of 5 years from the date of creation of the VCP (with standard leaver clauses).

· Corporate activities, such as new share issues or acquisitions, will be excluded from the growth calculation.

· For the majority of employees, awards will be settled in shares. For Lord Drayson, awards may be settled in cash or a mix of cash and shares (to the extent that this is permissible under the City Code on Takeovers and Mergers.

· Lord Drayson will not accrue any benefit under the scheme until the share price reaches 175p.

 

The table below shows the proportion of growth to be allocated over the five-year period of the VCP. The VCP is capped and there is no further allocation to the VCP above a market capitalisation of £1 billion. By way of example, the total value of the VCP at a market capitalisation of £300 million would be c.£18.9 million.

 

Market cap up to:

Share of growth above hurdle

£100m

15%

£150m

12.5%

£300m

7.5%

>£300m

5%

 

 

The forecast maximum dilution from the Plan would be 5.9%. Whilst this is in excess of the conventional 5% in 10 years, the Board believes this is justified to recruit and retain high calibre personnel in a competitive environment.

 

The VCP is considered to be a related party transaction under the AIM Rules for Companies by virtue of Lord Drayson's participation in the plan. The Non-executive directors, having consulted with Peel Hunt as the Company's nominated adviser, consider the terms of the VCP and the potential rewards to be fair and reasonable in so far as shareholders are concerned.

 

 

-ENDS-

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Michael Norris, Interim Chief Financial Officer

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden

James Steel

Oliver Jackson

Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma

Euan Brown

Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner

CSCsensynehealth@consilium-comms.com

 

 

About Sensyne Health 

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZGFLKGRGGZG
Date   Source Headline
31st Jul 20197:00 amRNSCollaboration Agreement with Bayer
9th Jul 20197:00 amRNSHoldings in Company
1st Jul 20192:05 pmRNSSecond Price Monitoring Extn
1st Jul 20192:00 pmRNSPrice Monitoring Extension
27th Jun 20194:48 pmRNSHolding(s) in Company
27th Jun 20194:42 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSEY announcement on AI and blockchain
24th Jun 20197:00 amRNSLAB10x partnership for data-driven drug discovery
30th Apr 20197:00 amRNSBayer joins Sensyne Health consortium
28th Jan 20197:02 amRNSResearch alliance with Big Data Institute
28th Jan 20197:02 amRNSAgreement with Jefferson Health in US
28th Jan 20197:02 amRNSSigns SRA with Wye Valley NHS Trust
28th Jan 20197:02 amRNSSigns SRA with George Eliot Hospital NHS Trust
28th Jan 20197:02 amRNSSensyne Health Maiden Interim Results 2018
15th Jan 20197:00 amRNSNotice of Interim Results
5th Dec 201810:41 amRNSAnnouncement on National Health Data
21st Nov 20187:00 amRNSStrategic advisory services agreement with EY
24th Oct 20187:00 amRNSBoard Change
16th Oct 20187:00 amRNSOfficial product launch of GDm-HealthT
3rd Oct 20187:00 amRNSBoard Appointment
2nd Oct 20187:00 amRNSChange of Registered Office
28th Sep 201811:56 amRNSHolding(s) in Company
6th Sep 20181:19 pmRNSSensyne Health welcomes government code of conduct
21st Aug 20183:28 pmRNSHoldings in Company
20th Aug 20185:32 pmRNSHoldings in Company
20th Aug 20184:52 pmRNSHoldings in Company
17th Aug 20188:04 amRNSAdmission to AIM & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.